Evaluating the Feasibility of Performing Window of Opportunity Trials in Breast Cancer

Table 3

Association between Ki67 labelling index and cleaved caspase 3 (CC3) values at baseline (before anastrozole) and surgery (after anastrozole) using the Spearman ( value) for associations.

	Baseline Ki67	Surgical Ki67	% change Ki67	Absolute change Ki67	Drug duration
Baseline CC3	−0.25
	(0.14)
Surgical CC3		0.06
		(0.74)
% change CC3			−0.02		−0.50
			(0.90)		(0.026)
Absolute change CC3				−0.17	−0.43
				(0.33)	(0.060)
Drug duration			0.23	0.07
			(0.32)	(0.76)